Stéphane M.
- Country
- France
- Department
- Hématologie
Research Overview
- Phase 3 Randomized Trial of Teclistamab Plus Daratumumab SC vs. Daratumumab SC with Pomalidomide and Dexamethasone or Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma
- Phase 2 Multicenter Open-Label Study of Ixazomib, Iberdomide, and Dexamethasone in Elderly Patients with Multiple Myeloma at First Relapse
Data & Insights
Has run more than one trial at 9 of 81 partner sites.
Specializations
Hematologic Oncology
This investigator specializes in treating multiple myeloma, with particular emphasis on managing relapsed and refractory cases.
- Multiple Myeloma Management
- Refractory Disease Treatment
- Elderly Patient Care
The investigator focuses on evaluating novel therapeutic combinations for multiple myeloma patients.
Treatment Innovation
The investigator explores innovative therapeutic combinations including both established and emerging treatments for blood cancers.
- Novel Drug Combinations
- Oral Treatment Regimens
- Targeted Therapies
Their work encompasses evaluation of various treatment approaches in different patient populations.
Patient-Specific Approaches
The investigator develops specialized treatment strategies for specific patient groups, including elderly populations with multiple myeloma.
- Age-Specific Protocols
- First Relapse Management
- Treatment Response Assessment
Their research includes evaluation of treatment efficacy in various patient subgroups.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.